Ariana Pharma in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results from a post hoc analysis of CY6463 first-in-human studies at the 2022 Clinical Trials On Alzheimer’s Disease (CTAD)

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials

Cambridge, MA, USA and Paris, France, November 30^th, 2022 – Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results from a post hoc analysis of CY6463 first-in-human studies at the 2022 Clinical Trials On Alzheimer’s Disease (CTAD) international conference held in San Francisco, USA. To know more